Peptostreptococcal pericarditis complicating anti-tumour necrosis factor α treatment in rheumatoid arthritis
| Autor: | F D O'Shea, S Harney, O FitzGerald |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Necrosis Letter business.industry Incidence (epidemiology) Immunology medicine.disease Placebo Gastroenterology General Biochemistry Genetics and Molecular Biology Infliximab Surgery Pericarditis Rheumatology Rheumatoid arthritis Internal medicine Deformity Immunology and Allergy Medicine Tumor necrosis factor alpha medicine.symptom business medicine.drug |
| Popis: | Rheumatoid arthritis (RA) is a common cause of disability and deformity for which treatment is often of limited value in controlling the disease process and outcome.1 Infliximab (chimeric antibody to tumour necrosis factor α (TNFα)) is clearly efficacious in up to 70% of patients, but treatment may be complicated by the development of infections that are occasionally serious and life threatening. Pooled analysis reported a 21% incidence of infection among 453 patients treated with infliximab compared with an 11% incidence in 109 placebo recipients.2 Infections considered serious occurred in 3.4% and 1.8% of patients, respectively. As of August 2001, 84 of 170 000 patients treated with infliximab world wide had developed active tuberculosis, including 14 deaths. Here we present the case of a 57 year old man with a five year … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|